[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centessa Pharmaceuticals (UK) Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,65,78,102,125,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100053299","phase-2-a-study-to-investigate-the-effects-of-cleminorexton-compared-with-placebo-in-the-treatment-of-participants-with-central-disorders-of-hypersomnolence-100053299",false,"NCT07598708","A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence","A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence","Key Inclusion Criteria:\n\n* 18-70 years of age\n* Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg\u002Fm\\^2 (inclusive)\n* Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria\n* Is willing and able to discontinue all medications used for the treatment of narcolepsy\n* Is willing and able to adhere to additional protocol requirements\n\nKey Exclusion Criteria:\n\n* Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)\n* Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease","ALL","18 Years","70 Years",{"count":20,"type":21},222,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \\[EDS\\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.\n\nWhile all conditions result in feeling sleepy, there are some differences in other common symptoms:\n\n* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.\n* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.\n\nOrexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.",[28,29],"Narcolepsy Type 1","Narcolepsy Type 2",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,28,29,47,48,49,50,51],"NT1","NT2","Excessive Daytime Sleepiness","Orexin Receptor 2 agonist","Central Disorders of Hypersomnia","Disorders of Excessive Somnolence","Dyssomnias","Nervous System Diseases","Mental Disorders","Hypersomnia","Hypersomnolence","Sleep Wake Disorders","Sleep Disorder","Sleep","Sleepiness","Cataplexy","Orexin","ORX750","Cleminorexton","Narcolepsy","SAPPHIRE","RECRUITING","2026-07-09",{"date":55,"type":56},"2026-07-13","ACTUAL",{"date":58,"type":56},"2026-05-29",{"date":60,"type":21},"2027-12-31",{"name":62,"class":63},"Centessa Pharmaceuticals (UK) Limited","INDUSTRY",7,{"id":66,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":26,"conditions":69,"keywords":70,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":77},"100642941",{"count":20,"type":21},[24,25],[28,29],[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,28,29,47,48,49,50,51],"2026-06-29",{"date":73,"type":56},"2026-07-01",{"date":58,"type":56},{"date":60,"type":21},{"name":62,"class":63},5,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100573929","phase-2-a-study-of-orx750-in-participants-with-narcolepsy-and-idiopathic-hypersomnia-100573929","NCT06752668","A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia","A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)","CRYSTAL-1","Inclusion Criteria:\n\n* 18-65 years of age\n* BMI ≥17 and ≤37 kg\u002Fm2\n* Meets the diagnostic criteria of Narcolepsy Type 1 (NT1), Type 2 (NT2) or Idiopathic Hypersomnia (IH) according to ICSD-3-TR criteria\n* Is willing and able to discontinue all medications used for the treatment of narcolepsy or idiopathic hypersomnia\n* Is willing and able to adhere to additional protocol requirements\n\nExclusion Criteria:\n\n* A medical disorder other than NT1, NT2, or IH that is associated with excessive daytime sleepiness (EDS).\n* Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease","65 Years",{"count":88,"type":21},248,[24],"Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \\[EDS\\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.\n\nWhile all conditions result in feeling sleepy, there are some differences in other common symptoms:\n\n* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.\n* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.\n* IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up.\n\nOrexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.",[28,29,92],"Idiopathic Hypersomnia","2026-04-22",{"date":95,"type":56},"2026-04-27",{"date":97,"type":56},"2024-12-23",{"date":99,"type":21},"2026-12",{"name":62,"class":63},37,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100600375","phase-2-a-long-term-extension-study-of-orx750-in-participants-with-narcolepsy-and-idiopathic-hypersomnia-100600375","NCT07096674","A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia","A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)\n* Is willing and able to adhere to additional protocol requirements\n\nExclusion Criteria:\n\n* Development of any new disease\u002Fdisorder that in the opinion of the investigator would make the participant unable to continue the study\n* Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia",{"count":110,"type":21},90,[24],"This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).",[28,29,92],[31,32,115,50,28,29,92,33,34],"IH","2026-04-15",{"date":118,"type":56},"2026-04-16",{"date":120,"type":56},"2025-08-12",{"date":122,"type":21},"2026-04-30",{"name":62,"class":63},24,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100624748","phase-1-a-study-of-orx489-in-healthy-adult-participants-aged-18-to-60-years-100624748","NCT07413666","A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years","A Safety, Tolerability, Pharmacokinetic, Food Effect, and Proof-of-Concept Study of Single and Multiple Doses of ORX489 in Healthy Adults","Inclusion Criteria:\n\n* Healthy males or females as determined by assessments at the Screening Visit.\n* For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening\n\nExclusion Criteria:\n\n* Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.\n* History of seizure disorder, any other condition that increases the risk of seizure\n* Has a clinically significant sleep disorder, including insomnia or sleep apnea",true,"60 Years",{"count":135,"type":21},212,[137],"PHASE1","Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.",[140],"Healthy Adult Male and Female Volunteers",[142],"Healthy Volunteers orexin-2 receptor agonist","2026-02-23",{"date":145,"type":56},"2026-02-25",{"date":145,"type":21},{"date":148,"type":21},"2027-06-30",{"name":62,"class":63},1,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":132,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100599310","phase-1-a-study-of-orx142-in-healthy-adult-subjects-including-subjects-18-to-80-years-of-age-100599310","NCT07082829","A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age","A Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of ORX142 in Healthy Adults, Single Doses of ORX142 in Healthy Older Adults, and a Single Dose Crossover, Proof-of-concept Study of ORX142 in Acutely Sleep-deprived Healthy Subjects","Key Inclusion Criteria:\n\n1. Healthy males or females as determined by assessments at the Screening Visit.\n\n   For Parts A, B, C, and E:\n\n   a. Participants must be at least 18 years of age and no more than 55 years of age at the Screening\n2. For Part D:\n\na .Participants must be at least 60 years of age and no more than 80 years of age at the Screening\n\nKey Exclusion Criteria:\n\n1. Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.\n2. History of seizure disorder, any other condition that increases the risk of seizure\n3. Has a clinically significant sleep disorder, including insomnia or sleep apnea.","80 Years",{"count":160,"type":21},208,[137],"Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.",[33],[33,165],"orexin-2 receptor agonist","2025-12-17",{"date":168,"type":56},"2025-12-24",{"date":170,"type":56},"2025-06-30",{"date":172,"type":21},"2026-06-15",{"name":62,"class":63},3,""]